05-JUL-2022 6:10

LUNG ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1701-Thymic Adv, Carbo/Pac/Ram vs. Carbo/Pac 1 Y 1 Ramucirumab + Carbo/Paclitaxel 66 8 0 0 0 0 0 03/20/2019 123 40
        2 Carboplatin + Paclitaxel   10 5 2 2 0 0      
            18 5 2 2 0 0      
 
  S1800D-Non-Match: N-803 + Pembro vs SoC 1 Y 1 Standard of Care (Inv. Choice) 478 13 13 13 11 4 0 03/15/2022 317 119
        2 N-803 (ALT-803) + Pembrolizumab   12 12 12 11 3 0      
            25 25 25 22 7 0      
 
  S1827-SCLC, MRI Surveillance +/- PCI 1 Y 1 PCI + MRI brain surveillance 668 50 25 15 6 2 0 05/04/2020 323 122
        2 MRI brain surveillance   52 26 17 9 3 0      
            102 51 32 15 5 0      
 
  S1900E-KRAS G12C: Sotorasib (AMG 510) 1 Y 1 Sotorasib (AMG 510) 116 66 47 18 8 2 1 04/16/2021 329 121
            66 47 18 8 2 1      
 
  S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo 1 Y 1 Atezolizumab and SBRT 480 56 37 19 11 4 1 08/13/2020 298 113
        2 SBRT   52 34 17 7 2 0      
            108 71 36 18 6 1      
 
  S1929-ESCLC, SLFN11+, Atezolizumab ± Talazoparib 1 Y 0 Screening 94 281 174 103 55 16 3 07/20/2020 222 81
            281 174 103 55 16 3      
 
    2 Y 1 Atezolizumab   41 26 14 11 2 1 07/20/2020    
        2 Atezolizumab + Talazoparib   42 28 15 9 4 0      
            83 54 29 20 6 1      
 
  S1933-NSCLC, Stg II-III, RT + Atezo 1 Y 1 Hypofractionated Radiotherapy 47 23 17 5 2 1 0 01/13/2021 107 39
            23 17 5 2 1 0      
 
    2 Y 2 Atezolizumab   17 16 6 3 1 0 01/13/2021    
            17 16 6 3 1 0      
 
  LUNGMAP-NSCLC, Adv, Master 1 Y 1 Biomarker Profiling   2567 473 291 176 50 9 02/06/2019 430 185
            2567 473 291 176 50 9      
 
Yes A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO 1 E Total Registrations   36 20 5 4 2 0 10/20/2020 404 183
            36 20 5 4 2 0      
 
  A151216-ALCHEMIST0 - screening 1 E Total Registrations   916 35 7 5 3 0 12/16/2014 475 246
            916 35 7 5 3 0      
 
  E4512-ALCHEMIST2, ALK mut, Crizotinib 1 E Total Registrations   17 1 0 0 0 0 02/29/2016 473 231
            17 1 0 0 0 0      
 
  EA5163-NSCLC, Immunotherapy +/- 2nd line therapy 1 E Total Registrations   52 12 7 3 2 0 05/30/2019 384 137
            52 12 7 3 2 0      
 
  EA5181-NSCLC, Unresect Stg 3, Chemo/RT+/-MED4736 1 E Total Registrations   40 20 10 5 0 0 08/03/2020 300 103
            40 20 10 5 0 0      
 
    2 E Total Registrations   32 20 15 9 5 2 08/03/2020    
            32 20 15 9 5 2      
 
  EA5182-NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 1 E Total Registrations   3 2 1 1 1 0 04/28/2021 156 75
            3 2 1 1 1 0      
 
  EA5191-NSCLC, Cabozantinib +/- Nivolumab vs Chemo 0 E Total Registrations   6 4 3 0 0 0 11/02/2020 203 82
            6 4 3 0 0 0      
 
    1 E Total Registrations   5 3 3 0 0 0 11/02/2020    
            5 3 3 0 0 0      
 
  NRGCC003-SCLC, PCI or HA-PCI 1 E Total Registrations   5 1 0 0 0 0 10/20/2016 222 115
            5 1 0 0 0 0      
 
    2 E Total Registrations   5 1 0 0 0 0 10/20/2016    
            5 1 0 0 0 0      
 
  NRGLU002-LUNG, Limited Met NSCLC, MST vs LCT + MST 1 E Total Registrations   2 0 0 0 0 0 11/06/2019 302 125
            2 0 0 0 0 0      
 
No A151216-ALCHEMIST0 - screening 0 E Total Registrations   929 36 8 6 4 1 12/16/2014 475 246
            929 36 8 6 4 1      
 
  NRGLU005-LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo 1 E Total Registrations   14 8 5 0 0 0 08/16/2019 385 151
            14 8 5 0 0 0      
 
  R1308-Lung, Stg II/III, Photon vs Proton Chemo RT 1 E Total Registrations   1 1 0 0 0 0 09/30/2021 32 27
            1 1 0 0 0 0      
 

05-JUL-2022 6:10

LUNG Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs
# of
CURR
IRBs
S1934 Superior Sulcus NSCLC, Trimodality +/- Atezo 1 Randomization 09-Sep-21 56 28
  2 Surgery 09-Sep-21 56 28
  3 Maintenance 09-Sep-21 56 28